Race Oncology Limited (RAC.XA)
| Previous close | 1.1900 |
| Open | 1.2150 |
| Bid | 1.2050 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 1.1950 - 1.2650 |
| 52-week range | 0.6400 - 1.8700 |
| Volume | |
| Avg. volume | 16,462 |
| Market cap | N/A |
| Beta (5Y monthly) | 1.50 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Race Strategic Update August 2023
Race Oncology Limited ("Race") is pleased to provide a strategic update, including an overview of revisions to corporate strategy, designed to optimise use of existing resources, while driving bisantrene's commercial partnering and collaboration potential.
- PR Newswire
Race executes agreement with Ardena for GMP manufacturing of RC220
Race Oncology Limited ("Race") is pleased to announce that it has signed an agreement with leading global contract development and manufacturing organisation (CDMO), Ardena Holding NV (Ardena) to provide additional Good Manufacturing Practice (cGMP)-standard manufacturing capability for Race's flagship intravenous (IV) formulation of bisantrene, RC220.
- PR Newswire
Race executes global license agreement with City of Hope to access FTO IP
Race Oncology Limited ("Race") is pleased to announce execution of an exclusive licence agreement ("Agreement") to access U.S. cancer research and treatment organisation City of Hope's intellectual property ("IP") which highlights bisantrene as a potent inhibitor of the human fat mass and obesity-associated protein, or FTO. City of Hope, one of the largest cancer research and treatment centres in the United States and a leading research centre for diabetes and other life-threatening illnesses, e
